Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECUR-506 in neonatal ornithine transcarbamylase deficiency
ISRCTN10957794Phase 2Recruiting
- Sponsor
- Fortrea
- Start
- Apr 2024
- Modality
- Gene Therapies
01
Overview
Phase 2, open-label trial of ECUR-506 in ornithine transcarbamylase deficiency (3 cohorts), sponsored by Fortrea. Primary endpoints: Treatment-emergent adverse events, Physical examination parameters and 5 more. Started Apr 2024; status: recruiting.
02
Drugs
ECUR-506
03
Conditions
ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on ISRCTN10957794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10957794.